{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:24:09Z","timestamp":1722039849964},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,26]]},"DOI":"10.7759\/cureus.65416","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T11:22:28Z","timestamp":1721992948000},"source":"Crossref","is-referenced-by-count":0,"title":["Response to Azacytidine in a Patient With Refractory Peripheral T-cell Lymphoma With TET2 Mutation"],"prefix":"10.7759","author":[{"given":"Minh-Anh","family":"Le","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feras","family":"Al-Moussally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Carilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_1849_17","article-title":"Peripheral T cell lymphoma","volume":"147","author":"Patel M","year":"2018","unstructured":"Patel M. Peripheral T cell lymphoma. Indian J Med Res. 2018, 147:439-41. 10.4103\/ijmr.IJMR_1849_17","journal-title":"Indian J Med Res"},{"key":"ref2","article-title":"Peripheral T-Cell Lymphoma","author":"Rangoonwala HI","year":"2024","unstructured":"Rangoonwala HI, Cascella M. Peripheral T-Cell Lymphoma. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow SH","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al.. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016, 127:2375-90. 10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1101441","article-title":"PTCL, NOS: an update on classification, risk-stratification, and treatment","volume":"13","author":"Weiss J","year":"2023","unstructured":"Weiss J, Reneau J, Wilcox RA. PTCL, NOS: an update on classification, risk-stratification, and treatment. Front Oncol. 2023, 13:1101441. 10.3389\/fonc.2023.1101441","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3142","article-title":"Peripheral T-cell lymphomas","volume":"41 Suppl 1","author":"Broccoli A","year":"2023","unstructured":"Broccoli A, Zinzani PL. Peripheral T-cell lymphomas. Hematol Oncol. 2023, 41 Suppl 1:82-7. 10.1002\/hon.3142","journal-title":"Hematol Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24992","article-title":"Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL)","volume":"93","author":"Zhang JY","year":"2018","unstructured":"Zhang JY, Briski R, Devata S, et al.. Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL). Am J Hematol. 2018, 93:394-400. 10.1002\/ajh.24992","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi L","year":"2021","unstructured":"Falchi L, Ma H, Klein S, et al.. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021, 137:2161-70. 10.1182\/blood.2020009004","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, international T-cell project","volume":"103","author":"Bellei M","year":"2018","unstructured":"Bellei M, Foss FM, Shustov AR, et al.. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, international T-cell project. Haematologica. 2018, 103:1191-7. 10.3324\/haematol.2017.186577","journal-title":"Haematologica"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.106171","article-title":"Allogeneic stem cell transplant provides durable response in peripheral T-cell lymphoma","volume":"83","author":"Modi D","year":"2019","unstructured":"Modi D, Surapaneni M, Kim S, et al.. Allogeneic stem cell transplant provides durable response in peripheral T-cell lymphoma. Leuk Res. 2019, 83:106171. 10.1016\/j.leukres.2019.106171","journal-title":"Leuk Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01545-w","article-title":"Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL","volume":"36","author":"Kameda K","year":"2022","unstructured":"Kameda K, Kako S, Kim SW, et al.. Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. Leukemia. 2022, 36:1361-70. 10.1038\/s41375-022-01545-w","journal-title":"Leukemia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225699","article-title":"Targeting TET2 as a therapeutic approach for angioimmunoblastic T cell lymphoma","volume":"14","author":"Hu L","year":"2022","unstructured":"Hu L, Zhang X, Li H, Lin S, Zang S. Targeting TET2 as a therapeutic approach for angioimmunoblastic T cell lymphoma. Cancers (Basel). 2022, 14:5699. 10.3390\/cancers14225699","journal-title":"Cancers (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22157","article-title":"Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes","volume":"8","author":"Cedena MT","year":"2017","unstructured":"Cedena MT, Rapado I, Santos-Lozano A, et al.. Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. Oncotarget. 2017, 8:106948-61. 10.18632\/oncotarget.22157","journal-title":"Oncotarget"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier F","year":"2012","unstructured":"Lemonnier F, Couronn\u00e9 L, Parrens M, et al.. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012, 120:1466-9. 10.1182\/blood-2012-02-408542","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000675","article-title":"Azacytidine and venetoclax in relapsed and refractory patients with angioimmunoblastic T-cell lymphoma","volume":"6","author":"Laribi K","year":"2022","unstructured":"Laribi K, Baugier de Materre A, Touileb Y, et al.. Azacytidine and venetoclax in relapsed and refractory patients with angioimmunoblastic T-cell lymphoma. Hemasphere. 2022, 6:e675. 10.1097\/HS9.0000000000000675","journal-title":"Hemasphere"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009445","article-title":"Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma","volume":"7","author":"Kalac M","year":"2023","unstructured":"Kalac M, Jain S, Tam CS, et al.. Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma. Blood Adv. 2023, 7:3760-3. 10.1182\/bloodadvances.2022009445","journal-title":"Blood Adv"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145495","article-title":"High rates of remission with the initial treatment of oral azacitidine plus chop for peripheral T-cell lymphoma (PTCL): clinical outcomes and biomarker analysis of a multi-center phase II study","volume":"138","author":"Ruan J","year":"2021","unstructured":"Ruan J, Moskowitz AJ, Mehta-Shah N, et al.. High rates of remission with the initial treatment of oral azacitidine plus chop for peripheral T-cell lymphoma (PTCL): clinical outcomes and biomarker analysis of a multi-center phase II study. Blood. 2021, 138:138. 10.1182\/blood-2021-145495","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02226-1","article-title":"Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study","volume":"59","author":"Moser O","year":"2024","unstructured":"Moser O, Ngoya M, Galimard JE, et al.. Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study. Bone Marrow Transplant. 2024, 59:604-14. 10.1038\/s41409-024-02226-1","journal-title":"Bone Marrow Transplant"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/271102-response-to-azacytidine-in-a-patient-with-refractory-peripheral-t-cell-lymphoma-with-tet2-mutation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T11:22:31Z","timestamp":1721992951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/271102-response-to-azacytidine-in-a-patient-with-refractory-peripheral-t-cell-lymphoma-with-tet2-mutation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.65416","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}